# Ark Genomic Revolution Ucits ETF AccumUSD (ARCG)

**Source:** https://fundology.uk/fund/arcg · ISIN IE000O5M6XO1 · Data: TradingView (LSE closes and returns, delayed), issuer documents, ONS CPIH, FCA FIRDS

## At a glance

> Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.

As of 30/09/2026, ARCG (Ark Genomic Revolution Ucits ETF AccumUSD, ISIN IE000O5M6XO1) closed at £7.69 on the London Stock Exchange. Its ongoing charge is 0.79% a year (about £79 on £10,000). Over the year to 30/09/2026 its total return was +99.2%, or +93.0% after UK CPIH inflation.

## Summary

Ark Genomic Revolution Ucits ETF AccumUSD is an exchange-traded fund (ETF) from ARK, launched in 2024. It tracks the No Underlying Index. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.79% a year — about £79 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.

Latest close: **£7.69** (30/09/2026).

## Key facts

| Fact | Value |
|---|---|
| Ticker (LSE) | ARCG |
| ISIN | IE000O5M6XO1 |
| Category | Healthcare |
| Type | ETF |
| Provider | ARK |
| Income | Accumulating |
| Ongoing charge | 0.79% a year (£79 per £10,000) |
| Fund size | £67.0m |
| Launched | 2024 |
| Domicile | Ireland |

## Past returns (periods to 30/09/2026)

After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after ONS CPIH inflation.

| Window | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 1 year | +99.23% | +92.98% | income reinvested |

Returns: TradingView (delayed data). Inflation: ONS CPIH, latest month published.

## Calendar-year returns

Calendar-year returns of Ark Genomic Revolution Ucits ETF AccumUSD in pounds (price, with income reinvested in the fund): 2025 +15.5%; 2026 to 30/09/2026 +83.8%. Returns of Ark Genomic Revolution Ucits ETF AccumUSD in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +108.0%; to 30/09/2025: +2.5%.

| Year | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 2025 | +15.5% | +11.6% | Price |
| 2026 to 30/09/2026 | +83.8% | +78.7% | Price |

## Risk metrics

| Window | Volatility | Max drawdown |
|---|---|---|
| 1 year | 43.87% | -22.29% |

## Largest fall

Volatility of Ark Genomic Revolution Ucits ETF AccumUSD in pounds, annualised from weekly returns to 30/09/2026: 43.9% over 1 year. Largest fall in the price of Ark Genomic Revolution Ucits ETF AccumUSD since April 2024, in pounds: −37.0% from 14/02/2025 to 04/04/2025. The lowest 12-month return of Ark Genomic Revolution Ucits ETF AccumUSD in pounds (price, with income reinvested in the fund) since April 2024 was −24.2% (12 months to 23/05/2025); the highest was +102.2% (12 months to 25/09/2026). On 30/09/2026 the price of Ark Genomic Revolution Ucits ETF AccumUSD was at its highest weekly close since April 2024, in pounds.

## Charges compared with similar funds

Ongoing charge of Ark Genomic Revolution Ucits ETF AccumUSD 0.79% a year, as of 01/10/2026: 0 of the 17 other healthcare funds charge more, 0 the same and 17 less (share classes counted once).

## Charges & eligibility

- Ongoing charges figure (OCF): **0.79%** per year
- ISA eligible: yes
- SIPP eligible: yes

---

We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments.

Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.